sofosbuvir
Gilead receives EU approval for combo hepatitis C treatment
July 11, 2016Sales and Marketing Epclusa, Gilead, eu approval, sofosbuvir
Gilead Sciences (NASDAQ: GILD) has received a marketing authorisation approval from the European Commission for combination treatment Epclusa (sofosbuvir/velpatasvir) for …
Gilead presents data highlighting progress and efficacy in liver and hepatitis C therapies
April 20, 2016Research and Development, Sales and Marketing Gilead, harvoni, hepatitis, liver, sofosbuvir
Gilead (NASDAQ: GILD) has presented a broad range of results on its current and potential therapeutics at the International Liver …
Federal jury rules in MSD’s favour in Gilead blockbuster hepatitis C drug dispute
March 23, 2016Medical Communications, Research and Development Gilead, MSD, blockbuster, federal court, federal jury, hit, patents, sales, sales hit, sofosbuvir, sovaldi
Gilead’s dominance of the hepatitis C market is under severe threat after a federal jury ruled in favour of MSD …
Gilead’s Sovaldi wins Drug Discovery of the Year Award
December 16, 2015Research and Development British Pharmacological Society, Gilead, Gilead Sciences, hepatitis C, sofosbuvir, sovaldi
Gilead Science’s hepatitis C treatment Sovaldi has been awarded the British Pharmacological Society’s prestigious Drug Discovery of the Year 2016. …
FDA sued over failure to disclose Sovaldi data
June 30, 2015Sales and Marketing FDA, Gilead, hepatitis C, sofosbuvir, sovaldi
Two groups that campaign for wider access to medicines have filed a lawsuit against the FDA, in a bid to …
China rejects Gilead’s Sovaldi patent
June 24, 2015Research and Development, Sales and Marketing China, Gilead, hep C, sofosbuvir, sovaldi
Manufacturer of the blockbuster hepatitis C treatment Sovaldi Gilead has seen its application for a patent in China rejected following …
The Pharmafocus debate: Is the price of new hepatitis C treatments fair?
April 27, 2015Research and Development, Sales and Marketing Doctors of the World, Drug pricing, EFPIA, Gilead, MSF, drug cost, hepatitis C, patents, sofosbuvir, sovaldi
YES – says Richard Bergström, director general of the European Federation of Pharmaceutical Industries and Associations (EFPIA), who argues that …
Gilead presents new Sovaldi data
April 23, 2015Sales and Marketing GS-5816, GS-9857, Gilead, NS3/4A, SVR12, hepatitis C, sofosbuvir, sovaldi
Gilead is looking to several new studies to support future new Sovaldi combinations and broadened treatment groups for its hepatitis …
$10 generic Solvaldi emerges in Bangladesh
March 10, 2015Manufacturing and Production, Sales and Marketing Gilead, World Trade Organization, hep C, incepta, sofosbuvir, sofosbuvir), sovaldi
A Bangladeshi pharma company is producing an unlicensed generic version of Gilead’s hepatitis C drug Sovaldi for $10 per pill …
Gilead frustrated despite final NICE Sovaldi nod
February 25, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, sofosbuvir, sovaldi
NICE has published final guidance confirming its approval of Gilead’s controversial blockbuster hepatitis C treatment Sovaldi – but Gilead and …
Pharma is boosting pipelines to avoid patent cliff
February 11, 2015Sales and Marketing Biogen IDEC, Moody's, dimethyl fumarate, lilly, pharma, pipelines, sofosbuvir, sovaldi, tecfidera
Pharmaceutical companies have improved their pipelines of new drugs over the last 18 months according to financial analysts Moody’s Investors …
Charity challenges Sovaldi patent
February 10, 2015Sales and Marketing Gilead, HCV, Médecins du Monde, sofosbuvir, sovaldi, world health organization
Doctors of the World (also known as Médecins du Monde) has filed an opposition to the patent for Gilead’s blockbuster …
Pharma adverse event FDA reports are inadequate
February 5, 2015Sales and Marketing FDA, Gilead, Solvaldi, US Institute for Safe Medication Practices, pharma, sofosbuvir
Reports of adverse drug events submitted to the FDA by pharma firms are often incomplete and lacking in detail, a …
Gilead sales soar on back of hepatitis drugs
February 4, 2015Sales and Marketing Atripla, Gilead, efavirenz, emtricitabine, harvoni, lepidasvir, q4, sofosbuvir, sovaldi, tenofovi
The new blockbuster hepatitis C treatments Sovaldi and Harvoni more than doubled Gilead’s sales in the last quarter of 2014 …
New drug added to generic Sovaldi licensing
January 26, 2015Manufacturing and Production, Sales and Marketing Gilead, HCV, hepatitis C, sofosbuvir, sovaldi
Gilead has expanded the licensing of generic versions of its blockbuster hepatitis C treatment Sovaldi to include a new experimental …
